期刊文献+

382株耐甲氧西林金黄色葡萄球菌的耐药性分析 被引量:1

Analysis of methicillin-resistant Staphylococcus aureus to commonly uscd antibiotics
原文传递
导出
摘要 目的了解本地区耐甲氧西林金黄色葡萄球菌的临床感染现状和耐药性,提供临床参考。方法采用法国梅里埃葡萄球菌鉴定试剂盒和ATBExpression仪鉴定细菌的种类,用纸片扩散法进行药敏试验。结果2007~2009年共分离金黄色葡萄球菌784株,其中耐甲氧西林金黄色葡萄球菌((MRsA)395株,检出率50.4%。全部金葡菌株对万古霉素和利奈唑胺都敏感,MRSA株对青霉素、红霉素、环丙沙星、左氧氟沙星、克林霉素、替考拉宁和复方新诺明的耐药率分剐为100%、94.4%、87.1%、80.0%、86.8%、71.6%和44.1%。结论MRSA的检出比率较高,耐药性严重。呈多重耐药,临床应高度重视对MRSA及其耐药性的检测,以帮助合理用药。 Aim To analyze the incidence and resistance of methicillin-resistant Staphylococcus aureus (MRSA) to common used antibiotics. Methods The bacterial strains were automatically identified with French Merieux aureus identification kits and ATB Expression,and then the antibiotic resistances were tested by standard Kirby-Bauer method. Results A total of 765 strains were isolated during 2007-2009,in which 382 were MRSA (49.9%). All isolates were susceptible to vancomycin and hnezolid. The resistant rate of the isolates of MRSA to penicillin, erythromycin, ciprofloxacin, levofloxacin,clindamycin,teicoplanin,and cotrimoxazole were 100% ,96.9% ,89.8% ,83.9% ,88.0% ,74.2% and 43.0%. Conclusions The isolation rate of MRSA increased significantly. For effective supervision and control of Staphylococcus aureus infection and dealing with multiple resistance,susceptibility survey of MRSA to antibiotics be performed to guide rational use of clinical drugs.
出处 《中国热带医学》 CAS 2011年第4期438-439,共2页 China Tropical Medicine
关键词 金黄色葡萄球菌 耐甲氧西林金黄色葡萄球菌(MRSA) 耐药性 Staphylococcus aureus Methicillin-resistant Staphylococcus aureus Drug resistance
  • 相关文献

参考文献9

二级参考文献21

  • 1胡健,杨敏贞,江映红,尘坚.我院近3年金黄色葡萄球菌耐药性调查分析[J].贵州医药,2005,29(1):79-81. 被引量:4
  • 2黄妮妮,刘洁.耐甲氧西林金黄色葡萄球菌感染流行病学调查[J].中华医院感染学杂志,2005,15(1):47-48. 被引量:53
  • 3Cox RA, Conquest C. Strategies forthe management of healthcare staff colonized with epidemic methicillin-resistantStaphylococcus aureus[J]. J Hosp Infect 1997, 35(2):117-127.
  • 4Humphreys H, Duckworth G. Methicillin-resistant Staphylococcus aureus (MRSA):are-appraisal in the light of changing circumstances[J]. J Hosp Infect 1997, 36(3):167-170.
  • 5National Committee for Clinical Laboratory Standards. Documents M7-A4. Performancestandards for antimirobial disk susceptibility tests. Approved standards[S]. NCCLS, 1998.17(2).
  • 6National Committee for Clinical Laboratory Standards. Documents M7-A4. Performancestandards for antimirobial disk susceptibility tests. Approved standards[S]. NCCLS, 1998.18(1).
  • 7Goldstein FW, Coutrot A, Sieffer A, et al. Percentages and distributions ofteicoplanin and vancomycin-resistant strains among coagulase-negative staphylococci[J].Antimicrob Agents Chemother, 1990, 34(5): 899-900.
  • 8Schentag JJ, Hyatt JM, Carr JR, et al. Genesis of methicillin -resistantStaphylococcus aureus (MRSA), how treatment of MRSA infections has selected forvancomycin-resistant Enterococcus faecium, and the importance of antibiotic management andinfection control[J]. Clin Infect Dis, 1998, 26(5): 1204-1214.
  • 9Goldrick B.First reported case of VRSA in the United States[J].Am J Nurs,2002,102(11):17.
  • 10张凤凯,金少鸿,吴铨,张力.北京地区部分医院细菌对常用抗生素耐药性现状及变迁[J].中华医学杂志,1997,77(5):327-331. 被引量:99

共引文献89

同被引文献12

  • 1Moellefing RC. Linezolid: the first oxazolidinone antimicrobial[J]. Ann Intern Med, 2003, 138(2): 135-142.
  • 2Prystowsky J, Siddiqui F, Chosay Jet al. Resistance to linezolid: char- acterization of mutations in rRNA and comparison of their occurrences in vaneomyein-resistant enterococei[J]. Antimierob Agents Chemoth- er, 2001, 45(7): 2154-2156.
  • 3Sander P, Belova L, Kidan YG, Pfister P, Mankin AS, Bottger EC. Ribo- somal and non-ribosomal resistance to oxazolidinones: species-specif- ic idiosyncrasy of ribosomal alterations[J]. Mol Microbiol, 2002, 46(5): 1295-1304.
  • 4Dandache P, Moise PA, Orsini J, Montecalvo M, Sakoulas G. Reduced biofilm production associated with increasing linezolid MICs among li- nezolid-resistant staphylococci[J]. J Antimierob Chemother, 2009, 64 (5):1114-1115.
  • 5Allen GP, Bierman BC. In vitro analysis of resistance selection by line- zolid in vancomycin-susceptible and-resistant Enterocoecus faecalis and Enterocoeeus faecium[J]. Int J Antimierob Agents, 2009, 34(1): 21-24.
  • 6Bourgeois-Nicolaos N, Massias L, Couson B, Butel MJ, Andremont A, Doueet-Populaire F. Dose dependence of emergence of resistance to linezolid in Enterococcus faeealis in vivo[J]. J Infect Dis, 2007, 195 (10): 1480-1488.
  • 7Shinabarger DL, Marotti KR, Murray RW et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation re- actions[J]. Antimlcrob Agents Chemother, 1997, 41(10): 2132-2136.
  • 8Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis[J]. Antimicrob Agents Chemother, 2002, 46 (10): 3334-3336.
  • 9Long KS, Vester B. Resistance to linezolid caused by modifications at its binding site on the ribosome[J]. Antimicrob Agents Chemother, 2012, 56(2): 603-612.
  • 10陈忠,张小云,黄云平,聂晓辉.院内耐甲氧西林金黄色葡萄球菌爆发感染控制分析[J].中国热带医学,2009,9(7):1332-1333. 被引量:8

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部